UK markets open in 6 hours 10 minutes

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
147.82+5.27 (+3.70%)
At close: 04:00PM EDT
147.50 -0.32 (-0.22%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close142.55
Open139.65
Bid147.74 x 400
Ask147.93 x 400
Day's range137.52 - 150.80
52-week range62.55 - 170.47
Volume4,921,158
Avg. volume4,061,353
Market cap56.651B
Beta (5Y monthly)1.57
PE ratio (TTM)N/A
EPS (TTM)-15.59
Earnings date01 Aug 2024 - 05 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est138.94
  • Yahoo Finance Video

    FDA considers updating COVID boosters, Novavax stock reacts

    The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.

  • Insider Monkey

    Is Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now?

    We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Moderna, Inc. (NASDAQ:MRNA) is the top gene therapy stock to invest in now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]

  • Benzinga

    Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients

    Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Merck’s Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of approximately three years (34.9 months), adjuvant tr